Optimising pathways between primary and secondary care.
Watch now ↓This promotional video series is Intended for UK healthcare professionals and has been developed and funded by Luye Pharma UK.
Zeyzelf (rivastigmine) Prescribing Information and Adverse Event Reporting Information can be found at the bottom of this website page.
This content is Intended for UK healthcare professionals. Zeyzelf® (rivastigmine) is indicated for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia.
Adverse events should be reported. Reporting forms and information can be found at: www.yellowcard.mhra.gov.uk Adverse events should also be reported to Luye Pharma Ltd at safety@luyepharma.co.uk
To access this information you must confirm that you are a healthcare professional.
This page is intended for media, journalists and investors.
Are you a member of the media, a journalist or investor?
To access this information you must confirm that you are a healthcare professional.